EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-SA 4.0

‘Lipotoxic cardiomyopathy’: A suspected case of lipotoxic infiltration of the myocardium

Tanuj Bhatia, Vanshaj Sharma, Anamika Gupta, Devendra Bisth, Kunal Mahajan

Indian Journal of Cardiology · 2025

DOI: 10.4103/ijoc.ijoc_9_25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Indian Journal of Cardiology, 2025. Verfasst von Tanuj Bhatia und 4 weiteren Autor:innen. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Hyperlipidemia, especially elevated low-density lipoprotein cholesterol (LDL-C) level, is a well-established risk factor for atherosclerotic cardiovascular disease (ASCVD).[1] However, a known but often overlooked effect of hyperlipidemia is its direct effect on the myocardium, independent of ischemic injury.[2] The term “Lipotoxic cardiomyopathy” coined by Zhou et al. in 2000 in studies of Zucker diabetic fatty (ZDF) rat models describes non-ischemic myocardial impairment associated with elevated blood lipid levels.[3] We present a case of suspected lipotoxic cardiomyopathy in a patient with heterozygous familial hypercholesterolemia. Case Report A 36-year-old male with no antecedent history of myocarditis presented with a history of ventricular tachycardia with haemodynamic compromise, requiring two cardioversions at an outside hospital. With no identifiable reversible cause of arrhythmia, he was referred to our hospital for further evaluation. On arrival, the patient was hemodynamically stable with normal vital signs. An electrocardiogram revealed normal sinus rhythm, frequent ventricular premature contractions (VPCs), and no ST-T segment changes. Blood work revealed severe hyperlipidemia with total cholesterol of 323 mg/dl, LDL-C 234 mg/dl, high density lipoprotein cholesterol (HDL-C) 30 mg/dl, triglycerides 295 mg/dl, and very low-density lipoprotein cholesterol (VLDL-C) 59 mg/dl. Echocardiography showed dilated cardiomyopathy with global hypokinesia, severe left ventricular dysfunction and a left ventricular ejection fraction of 25%. Coronary angiography (CAG) performed to rule out obstructive coronary artery disease revealed normal epicardial coronaries [Figure 1]. Given the severely reduced LVEF and documented ventricular arrhythmias, the patient was deemed at high risk for sudden cardiac death (SCD) and underwent implantation of a dual-chamber Automatic Implantable Cardioverter Defibrillator (AICD) (Boston Scientific) for primary prevention [Figure 2]. The patient was then discharged on optimal heart failure medications (Angiotensin Receptor Neprilysin Inhibitor (ARNI), beta blockers, mineralocorticoid receptor antagonist, and sodium-glucose cotransporter-2 (SGLT 2) inhibitors), moderate-intensity statin, and was followed up on outpatient basis.Figure 1: Coronary angiography showing absence of coronary artery diseaseFigure 2: Dual chamber automatic implantable cardioverter defibrillatorAfter a year, there was a moderate increase in LVEF to 30% on echocardiography. However, lipid levels remained elevated: total cholesterol 276 mg/dL, LDL-C 210 mg/dL, HDL-C 37 mg/dL, and triglycerides 142 mg/dL. These abnormal lipid values revealed a suspicion of familial hypercholesterolemia. Consequently, moderate intensity statin was elevated to high intensity statin, and ezetimibe and bempedoic acid were added to his regimen. Follow-up one year later revealed improved lipid levels: total cholesterol 192 mg/dL, LDL-C 139 mg/dL, HDL-C 28 mg/dL, and triglycerides 122 mg/dL. There was also a significant improvement in LVEF to 45%, correlating with the reduction in lipid levels. Although a speculation, but the improvement in LVEF concurrent with initiation of triple lipid lowering therapy including high intensity statins and in sync with reduction of LDL makes it plausible that elevated lipids were more than an innocent bystander and prompts us to evaluate lipotoxicity as a potential cause for non-ischemic dilated cardiomyopathy. In order to confirm our hypothesis of lipotoxic infiltration of the myocardium, a cardiac MRI was done using a 1.5 T machine which was compatible with the patient’s AICD, but a large number of artifacts made the images inconclusive. Complete genome sequencing revealed a mutation involving a heterozygous start loss variant in exon 1 of the LDL receptor gene (Chromosome 19 g.11089549A>T). This finding classified the patient as having ‘Definite Familial Hypercholesterolemia’ according to the ‘Dutch Criteria for Familial Hypercholesterolemia (FH)’. The genome sequencing did not document any known genetic mutations contributing to dilated cardiomyopathy which came back negative, ruling out the possibility of genetic dilated cardiomyopathy [Table 1]. Lists the genetic mutations associated with dilated cardiomyopathy and familial hypercholesterolemia for which the patient was screened.Table 1: List of genes associated with dilated cardiomyopathy and familial hypercholesterolemia for which the patient was screened forThese findings supported our hypothesis that the left ventricular dysfunction might be associated with hyperlipidemia and lipotoxicity.

Discussion

Cholesterol metabolism and its role in cardiovascular diseases was first described in detail in the 1970s.[6] Ever since then, great emphasis has been placed on its role in atherosclerosis, and over the years, guidelines have been curated and regularly updated with this in mind. This focus is well-justified, given that hyperlipidemia is one of the most important risk factors for atherosclerosis and coronary artery disease is a major cause of mortality and morbidity worldwide. With the rise of the obesity pandemic[7] and increased prevalence of other comorbidities such as diabetes mellitus[8] which impair lipid metabolism, the prevalence of hyperlipidemia is projected to increase. Considering this, some light should also be put on the non-atherosclerotic effects of hyperlipidemia especially in people with genetic conditions like familial hypercholesterolemia considering every 1 in 313 people suffer from it.[9] Various animal models have been studied to understand the effect of lipid accumulation in the myocardium. Excess calories may be stored in various non-adipose tissues such as myocardium in the form of triglycerides. ZDF rat models, who have leptin receptor mutation have increased calorie intake and lipogenesis. Such models had myocardial lipid accumulation, which was associated with left ventricular dysfunction and lipoapoptosis.[10] It has been observed that hypercholesterolemia is associated with the impairment of various important myocardial protein expression such as Sarcoendoplasmic reticulum calcium ATPase (SERCA), ryanodine receptors (RyR) and Na+/Ca2+ exchangers in rabbit models, which impairs the systolic and diastolic function of the heart.[11] Lipotoxicity is also mediated by increased oxidative stress, inflammation, and fibrosis.[12] Hyperlipidemia also suppresses connexin 43 which is an important component of gap junction between myocytes in rabbit models, impairing contractility.[13] Myocardial lipotoxicity also disrupts calcium homeostasis within the myocardium, leading to impaired calcium dynamics. This disruption significantly increases the risk of arrhythmias by altering the electrical stability and contractile function of the heart.[14] Speckle tracking echocardiography study for left ventricular systolic function done on patients with familial hypercholesterolemia showed subtle LV systolic dysfunction at an early age. Patients with homozygous familial hypercholesterolemia, who have more severe hyperlipidemia compared to heterozygous familial hypercholesterolemia, had ventricular dysfunction at an earlier age.[15] Similar results were replicated in another study of 49 patients with heterozygous familial hypercholesterolemia.[16] This highlights that though hyperlipidemia mainly affects the heart via its atherogenic potential, there is also some underlying ‘lipotoxic effect on the myocardium’ that impairs the systolic function of the heart.

Conclusion

The non-ischemic effect of hyperlipidemia is a known but under-recognized entity. Though our primary focus should remain on the atherogenic effect of hyperlipidemia on the heart, some focus should also be given to its direct effect on myocardium especially in cases where the patient’s clinical features cannot be explained by any other etiology. Declaration of patient consent The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.

Zitieren

APA

Bhatia, T., Sharma, V., Gupta, A., Bisth, D., & Mahajan, K. (2025). ‘Lipotoxic cardiomyopathy’: A suspected case of lipotoxic infiltration of the myocardium. Indian Journal of Cardiology. https://doi.org/10.4103/ijoc.ijoc_9_25

Vancouver

Bhatia T, Sharma V, Gupta A, Bisth D, Mahajan K. ‘Lipotoxic cardiomyopathy’: A suspected case of lipotoxic infiltration of the myocardium. Indian Journal of Cardiology. 2025. doi:10.4103/ijoc.ijoc_9_25

BibTeX
@article{Bhatia2025,
  author = {Bhatia, Tanuj and Sharma, Vanshaj and Gupta, Anamika and Bisth, Devendra and Mahajan, Kunal},
  title = {‘Lipotoxic cardiomyopathy’: A suspected case of lipotoxic infiltration of the myocardium},
  journal = {Indian Journal of Cardiology},
  year = {2025},
  doi = {10.4103/ijoc.ijoc_9_25}
}
Kostenlos starten →